Want to see GRTXD full AI Analyst Report?
Total Valuation
Galera Therapeutics has a market cap or net worth of $19.20M. The enterprise value is $950.89K.
Market Cap$19.20M
Enterprise Value$950.89K
Share Statistics
Galera Therapeutics has 1,040,118 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,040,118
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Galera Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count3
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Galera Therapeutics is <0.1. Galera Therapeutics’s PEG ratio is -0.00003.
PE Ratio<0.1
PS Ratio0.00
PB Ratio0.33
Price to Fair Value―
Price to FCF-0.36
Price to Operating Cash Flow―
PEG Ratio-0.00003
Income Statement
In the last 12 months, Galera Therapeutics had revenue of ― and earned ― in profits. Earnings per share was ―.
Revenue―
Gross Profit―
Operating Income―
Pretax Income―
Net Income―
EBITDA―
Earnings Per Share (EPS)―
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
Galera Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.01
52-Week Price Change179.26%
50-Day Moving Average18.74
200-Day Moving Average9.73
Relative Strength Index (RSI)37.89
Average Volume (3m)63.57K
Important Dates
Galera Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Galera Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Galera Therapeutics has paid ― in taxes.
Income Tax―
Effective Tax Rate―
Enterprise Valuation
Galera Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Galera Therapeutics has ― in cash and marketable securities with $0.00 in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt$0.00
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Galera Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―